CONDENSED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 30,387,583	$ 6,324,430
Marketable securities	11,057,672	20,567,861
Proceeds from sale of RXi, received January 6, 2011	0	6,938,603
Receivable	37,757	259,006
Investment in Adventrx Pharmaceuticals, at market	115,920	0
Income taxes recoverable	0	519,158
Interest receivable	22,555	117,624
Prepaid expenses and other current assets	2,663,184	1,247,145
Total current assets	44,284,671	35,973,827
Equipment and furnishings, net	293,564	319,191
Goodwill	183,780	183,780
Other assets	105,979	220,292
Total assets	44,867,994	36,697,090
Current liabilities:
Accounts payable	2,836,778	1,027,924
Accrued expenses and other current liabilities	4,332,397	2,663,910
Warrant liabilities	9,159,639	2,437,281
Total current liabilities	16,328,814	6,129,115
Commitment and contingencies
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 25,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding	0	0
Common stock, $.001 par value, 250,000,000 shares authorized; 149,060,885 and 109,840,445 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively	149,058	109,840
Additional paid-in capital	237,021,821	229,253,122
Accumulated comprehensive income, net of tax	115,920	0
Treasury stock, at cost (633,816 shares)	(2,279,238)	(2,279,238)
Accumulated deficit	(206,468,381)	(196,515,749)
Total stockholders' equity	28,539,180	30,567,975
Total liabilities and stockholders' equity	$ 44,867,994	$ 36,697,090